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Biomanufacturing, smart engineering and process intensification expertise

Univercells exists to make biologics available and affordable to all –
Downsizing production infrastructure by intensification
Biologics for all – CAPEX is usually the first barrier

Old paradigm

New paradigm

Centralized manufacturing for
developed economies
(e.g. USA, EU, Japan)

Distributed manufacturing for local
markets
(e.g. Asia, Africa, Latin America)

By reducing the CAPEX & COGs,
Univercells creates value for all:
> Manufacturer
– Affordable local facility
– Maintained margin
– Optimized pricing & market share
increase

> Healthcare systems
– Increased number of treated
patients
– Improved healthcare cost efficiency
– Autonomous supply for emerging
economies
Paradigm shift supported and promoted by all
health-related NGOs and academics, i.e. WHO,
BMGF, Wellcome Trust and MIT, UCL

Source: Univercells

> Patients
– Affordable treatment
– Increased quality of life
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This is achieved by bringing out the best of technology innovations
allowing a rapid deployment of low CAPEX/OPEX production facilities
Technology-driven affordability by applying chemical engineering rules
Low-footprint, high-performance process

Value
creation

Intensification
Use of high-density fixed-bed bioreactors
operated in perfusion, and high-performance
chromatography columns

Source: Univercells

Chaining
All unit steps are chained into an
integrated process, allowing
continuous operation from cell
culture to clarification and capture

> Dramatic reduction of
CAPEX & OPEX
> Rapid deployment of
multiproduct facilities
with a capacity of:
– 5-40M doses/year
for Vaccines
– 50-500 kg/year for
mAbs
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Cell culture is performed in a bioreactor to significantly increase celldensity, as a way to replace traditional manufacturing process
Increase efficiency in cell culture – Single-use fixed-bed Bioreactor
Traditional manufacturing
Scale-out
of lab
principle to
industrial
scale
4 RB* 20 RB

100 RB

600 RB

~7000 RB

> Limited innovation in
current vaccine
manufacturing
– Over 80% of viral
vaccines are still
manufactured by
the scaling out of
lab-scale systems

High cell-density bioreactor
Densification
4 RB

20 RB

of cell culture with
fixed bed singleuse bioreactor

> A 600m² fixed-bed
bioreactor replaces
~7000 RB in a
volume of ~50L

*Roller bottle

Source: Univercells
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Univercells developed NevoLine™, a low-footprint micro-facility for viral
production, chaining scale-X™ bioreactor with downstream processing
Viral production automated & integrated in cabinet

Culture

Purification

Inactivation

scale-X™ high-performance
fixed-bed bioreactor

In-line clarification
and purification

In contained
cabinet

High performance singleuse fixed-bed bioreactor
> Intensification of cell culture &
viral production process
> Drastic footprint reduction of
bioreactor equipment
> Enables process chaining &
containment

Source: Univercells
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NevoLine™ integrated fixed-bed bioreactor achieves high cell
density & viral titers, delivering high-volume, low-cost viral production
Experimental data – sIPV production process
Cell growth

Viral Productivity

Purification

> PV3, ~ 40x increase
> PV2, ~25x increase

> Good HCP and HCD
clearance

> Bioreactor size
decreased by 25 to 40x
compared to reference
process

> D-antigen recovery >90%
> One purification step
with high impact on
footprint and cost

> Reproducible cell growth
> Cell density at infection ~40M/ml

> With current small scale yields,
Univercells process would yield:
– ~1.6M doses/run purified

Source: Univercells

> With current small scale yields,
Univercells process would yield:
– ~0.7M doses/run purified
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NevoLine™ micro-facility can be confined in BSL-2/3 pods, for a
rapid deployment of high safety, low-footprint pod-based facilities

3
1

Miniaturization
of equipment

> Production automated &
contained in isolator
> Delivering low CoGs
Source: Univercells

2

Production in
low footprint facility
~1,500m² with 4 micro-facility skids

Containment in
isolator and pod

> Container-sized pod, BSL-1 to
BSL-3 classification depending
on pathogen

> Easily expandable
> Drastic CAPEX reduction
> Rapid deployment
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NevoLine™ achieves flexible & affordable viral production,
enabling their rapid availability during epidemic outbreaks
Zoom on key benefits

Cost-effectiveness
> Target CAPEX: ~€10-€20M
> Target CoGs trivalent sIPV: $0.15/dose
> Productivity on ~6m² footprint >10M
doses/y

Flexibility &
adaptability
Source: Univercells

Safety

> Automated, fully contained operations
> BSL2-3 compliant for safe production
of viruses such as Ebola, Marburg
fever, Lassa Fever

> Broadly applicable to viral vaccines with minor hardware adaptations
> Facilitating process development of new vaccines
> Easily switch production from one product to the other
©2018 Univercells. All Rights reserved
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These low-footprint and highly-contained production units are easily
and rapidly deployable, offering adapted solutions for rapid response
Univercells platform applications for epidemic preparedness & response

1
Rapid
2 deployement
Stand-by
3 production unit
Stockpiling

Source: Univercells

Cost-effective source to generate rotating stockpile of
pandemic vaccines
Deploy quick-reaction units to manufacture emergency
vaccines for emerging diseases
Install the micro-facility as preventive
mothball extended manufacturing
capacity, only to be reactivated during
time of crisis
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“Humanity’s greatest advances
are not in its discoveries, but in
how those discoveries are applied
to reduce inequity.” – Bill Gates

Icons designed by Madebyoliver and freepik from Flaticon

©2018 Univercells. All Rights reserved

10

Biologics
available to all !

